These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37042083)

  • 21. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
    Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
    Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spot urinary sodium in acute decompensation of advanced heart failure and dilutional hyponatremia: insights from DRAIN trial.
    Galluzzo A; Frea S; Boretto P; Pidello S; Volpe A; Canavosio FG; Golzio PG; Bergerone S; De Ferrari GM
    Clin Res Cardiol; 2020 Oct; 109(10):1251-1259. PubMed ID: 32144493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit.
    Buckley LF; Carter DM; Matta L; Cheng JW; Stevens C; Belenkiy RM; Burpee LJ; Young MA; Weiffenbach CS; Smallwood JA; Stevenson LW; Desai AS
    JACC Heart Fail; 2016 Jan; 4(1):1-8. PubMed ID: 26656139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natriuretic Equation to Predict Loop Diuretic Response in Patients With Heart Failure.
    Rao VS; Ivey-Miranda JB; Cox ZL; Riello R; Griffin M; Fleming J; Soucier R; Sangkachand P; O'Brien M; LoRusso F; D'Ambrosi J; Churchwell K; Mahoney D; Bellumkonda L; Asher JL; Maulion C; Turner JM; Wilson FP; Collins SP; Testani JM
    J Am Coll Cardiol; 2021 Feb; 77(6):695-708. PubMed ID: 33573739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study.
    MacFadyen RJ; Gorski JC; Brater DC; Struthers AD
    Br J Clin Pharmacol; 2004 May; 57(5):622-31. PubMed ID: 15089816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous versus intermittent use of furosemide in patients with heart failure and moderate chronic renal dysfunction.
    Zheng Z; Jiang X; Chen J; He D; Xie X; Lu Y
    ESC Heart Fail; 2021 Jun; 8(3):2070-2078. PubMed ID: 33689236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure.
    Ter Maaten JM; Rao VS; Hanberg JS; Perry Wilson F; Bellumkonda L; Assefa M; Sam Broughton J; D'Ambrosi J; Wilson Tang WH; Damman K; Voors AA; Ellison DH; Testani JM
    Eur J Heart Fail; 2017 Aug; 19(8):1014-1022. PubMed ID: 28105769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure.
    Testani JM; Brisco MA; Turner JM; Spatz ES; Bellumkonda L; Parikh CR; Tang WH
    Circ Heart Fail; 2014 Mar; 7(2):261-70. PubMed ID: 24379278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure.
    Testani JM; Hanberg JS; Cheng S; Rao V; Onyebeke C; Laur O; Kula A; Chen M; Wilson FP; Darlington A; Bellumkonda L; Jacoby D; Tang WH; Parikh CR
    Circ Heart Fail; 2016 Jan; 9(1):e002370. PubMed ID: 26721915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.
    Ballester MR; Roig E; Gich I; Puntes M; Delgadillo J; Santos B; Antonijoan RM
    Drug Des Devel Ther; 2015; 9():4291-302. PubMed ID: 26273191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
    Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
    Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial.
    Ter Maaten JM; Beldhuis IE; van der Meer P; Krikken JA; Coster JE; Nieuwland W; van Veldhuisen DJ; Voors AA; Damman K
    Eur J Heart Fail; 2022 Feb; 24(2):385-392. PubMed ID: 34791756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Loop Diuretics on the Fractional Excretion of Urea in Decompensated Heart Failure.
    Cox ZL; Sury K; Rao VS; Ivey-Miranda JB; Griffin M; Mahoney D; Gomez N; Fleming JH; Inker LA; Coca SG; Turner J; Wilson FP; Testani JM
    J Card Fail; 2020 May; 26(5):402-409. PubMed ID: 32007554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in brain natriuretic peptide in chronic heart failure patients treated with long-acting versus short-acting loop diuretics: J-MELODIC subanalysis.
    Fukui M; Tsujino T; Hirotani S; Ito H; Yamamoto K; Akasaka T; Hirano Y; Ohte N; Daimon T; Nakatani S; Kawabata M; Masuyama T
    Heart Vessels; 2017 Jul; 32(7):865-871. PubMed ID: 28105515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comprehensive review of the loop diuretics: should furosemide be first line?
    Wargo KA; Banta WM
    Ann Pharmacother; 2009 Nov; 43(11):1836-47. PubMed ID: 19843838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials.
    Kiernan MS; Stevens SR; Tang WHW; Butler J; Anstrom KJ; Birati EY; Grodin JL; Gupta D; Margulies KB; LaRue S; Dávila-Román VG; Hernandez AF; de Las Fuentes L;
    J Card Fail; 2018 Jul; 24(7):428-438. PubMed ID: 29482026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.
    Damman K; Kjekshus J; Wikstrand J; Cleland JG; Komajda M; Wedel H; Waagstein F; McMurray JJ
    Eur J Heart Fail; 2016 Mar; 18(3):328-36. PubMed ID: 26693947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload.
    Verbrugge FH; Dupont M; Bertrand PB; Nijst P; Penders J; Dens J; Verhaert D; Vandervoort P; Tang WH; Mullens W
    Acta Cardiol; 2015 Jun; 70(3):265-73. PubMed ID: 26226699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial.
    Cox ZL; Hung R; Lenihan DJ; Testani JM
    JACC Heart Fail; 2020 Mar; 8(3):157-168. PubMed ID: 31838029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.